KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Bio-Rad Laboratories (BIO) over the last 17 years, with Q4 2025 value amounting to $3.1 billion.

  • Bio-Rad Laboratories' Total Liabilities rose 1173.97% to $3.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $3.1 billion, marking a year-over-year increase of 1173.97%. This contributed to the annual value of $3.1 billion for FY2025, which is 1173.97% up from last year.
  • Latest data reveals that Bio-Rad Laboratories reported Total Liabilities of $3.1 billion as of Q4 2025, which was up 1173.97% from $3.0 billion recorded in Q3 2025.
  • Bio-Rad Laboratories' 5-year Total Liabilities high stood at $4.6 billion for Q3 2021, and its period low was $2.8 billion during Q4 2024.
  • Over the past 5 years, Bio-Rad Laboratories' median Total Liabilities value was $3.5 billion (recorded in 2021), while the average stood at $3.5 billion.
  • As far as peak fluctuations go, Bio-Rad Laboratories' Total Liabilities surged by 4459.67% in 2021, and later crashed by 2198.97% in 2022.
  • Bio-Rad Laboratories' Total Liabilities (Quarter) stood at $4.1 billion in 2021, then fell by 5.54% to $3.9 billion in 2022, then dropped by 8.45% to $3.6 billion in 2023, then dropped by 21.45% to $2.8 billion in 2024, then increased by 11.74% to $3.1 billion in 2025.
  • Its last three reported values are $3.1 billion in Q4 2025, $3.0 billion for Q3 2025, and $3.1 billion during Q2 2025.